Innovent Biologics Inc (OP:IVBXF)

10.29 -0.86 (-7.67%)

Streaming Delayed Price Updated: 9:30 AM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innovent Biologics Inc

< Previous 1 2 Next >

Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate ↗

September 28, 2021

Privately-held UNION therapeutics A/S and Innovent Biologics Inc's (OTC: IVBIY) subsidiary have entered into a strategic collaboration and license...

Via Benzinga

Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates ↗

August 27, 2021

Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development collaboration for oncology candidates. The...

Via Benzinga

Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer ↗

August 16, 2021

Innovent Biologics Inc (OTC: IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall...

Via Benzinga

Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients ↗

August 06, 2021

Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly And Co (NYSE: LLY) have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab...

Via Benzinga

Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer ↗

July 09, 2021

The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking...

Via Benzinga

Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China ↗

June 03, 2021

The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY)...

Via Benzinga

Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA ↗

May 18, 2021

The FDA has accepted to review Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly and Co's (NYSE: LLY) marketing application for sintilimab injection...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.